Q2 FY2026 · ended Jun 30, 2026 · Revenue $318,000, -46.4% YoY · Filed Aug 11, 2026
Absci Corp (ABSI) files with the SEC under industry code 8731, Services-Commercial Physical & Biological Research. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $318,000 and a net loss of $33.2 million. Free cash flow was -$27.6 million. As of Jun 30, 2026 it held $201.1 million in cash and investments and $3.7 million in total debt.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- ABSI (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Vancouver, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1672688
- Former names
- AbSci, LLC (until Dec 19, 2019)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- OmniAb, Inc. OABI
- NRC Health NRC
- Maxcyte, Inc. MXCT
All 17 Services-Commercial Physical & Biological Research companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $318,000 | $215,000 | $650,000 | $378,000 | $593,000 |
| Operating income | -$34.2M | -$30.8M | -$31.0M | -$30.2M | -$31.4M |
| Net income | -$33.2M | -$29.6M | -$29.6M | -$28.7M | -$30.6M |
| Diluted EPS | -$0.21 | -$0.19 | -$0.20 | -$0.20 | -$0.24 |
| Operating cash flow | -$27.6M | -$26.3M | -$29.2M | -$25.0M | -$16.9M |
| Free cash flow | -$27.6M | -$26.3M | -$29.3M | -$26.0M | -$17.1M |
| Total assets | $268.9M | $195.6M | $216.3M | $245.0M | $209.9M |
| Total liabilities | $22.8M | $23.6M | $26.8M | $34.7M | $36.5M |
| Stockholders' equity | $246.1M | $172.0M | $189.4M | $210.3M | $173.4M |
| Cash and investments | $201.1M | $130.5M | $156.1M | $185.1M | $38.0M |
| Total debt | $3.7M | $4.0M | $4.4M | $4.8M | $5.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Other events
|
Jun 24, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 5, 2026 | Jun 4, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
All 360 Absci Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.